The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831
- World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class
- The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class
- The NOX inhibitor therapeutic class has significant potential in fibrotic, inflammatory, neurodegenerative, and oncology disorders
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced that the World Health Organization (WHO) has recommended setanaxib as the international nonproprietary name (INN) for GKT831.